Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines. The company was founded in 2002 and is headquartered in Huzhou, China.
Research context
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.8% below its 200 day moving average.
From a valuation standpoint, the stock is 452.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 53.2.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd's total revenue rose by 66.2% to $232M since the same quarter in the previous year.
Its net income has increased by 136.1% to $122M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.4% to $70M since the same quarter in the previous year.
Based on the above factors, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd gets an overall score of 3/5.